Cancer News and Research

Latest Cancer News and Research

NanoString Technologies launches new solution to detect CNVs in human genomic samples

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of its early access program for a unique new solution that detects copy number variation in human genomic samples. The program was announced in conjunction with the company's participation in the European Human Genetics Conference in Gothenburg, Sweden.

From NanoString Technologies 10 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

A research team led by Dr. Nada Jabado at the MUHC Research Institute and Dr. Jacek Majewski at McGill University has proven for the first time that it is possible to identify any genetic disease in record time thanks to a powerful and reliable exome sequencing method. The exome, a small part of the genome ((less than) 2%), is of crucial interest with regard to research on genetic diseases as it accounts for 85% of mutations.

10 Jun 2010

Goodmans Interior Structures and Shore Memorial Hospital receives CEO Cancer Gold Standard accreditation

Goodmans Interior Structures and Shore Memorial Hospital have received CEO Cancer Gold Standard™ accreditation, recognizing commitment of these organizations to taking concrete actions to reduce the cancer risk of employees and their families through screenings, early detection, and healthy changes in lifestyle.

10 Jun 2010

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children's Research Hospital investigators.

10 Jun 2010

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.

10 Jun 2010

Clarient becomes preferred genetic testing lab for Generation Health

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced a new contractual agreement with Generation Health, Inc. (GH). This agreement makes Clarient a preferred genetic testing lab for GH, thereby ensuring reimbursement of diagnostic tests done for GH's nationwide network of payor clients and expanding Clarient's potential market. GH is a genetic benefit management company partially-owned by CVS Caremark, the nation's largest pharmacy healthcare provider.

10 Jun 2010

Human Genome Sciences submits BLA for BENLYSTA to FDA

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

10 Jun 2010

PCI Biotech rights issue oversubscribed

The Oslo-Axess-listed Norwegian biopharmaceutical company PCI Biotech Holding ASA today announced that it has raised NOK90 million through a new rights issue. The company received subscriptions for a total of approximately 3.36 million new shares. The initial offering was and remains 2,250,000 new shares, and the rights issue was thus oversubscribed by approximately 50 percent.

10 Jun 2010

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 Jun 2010

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

10 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Study to understand process of telomere shortening

A new study at the University of Leicester is examining a sequence of DNA- known as telomeres - that varies in length between individual.

10 Jun 2010

Investigative Workshop aims to discuss current achievements, challenges in modeling solid tumors

With high human mortality associated with cancerous tumors, there is a worldwide need for a better understanding of why a tumor starts to grow and what makes it continue to grow. Mathematical modeling can provide some of the answers.

10 Jun 2010

Spectrum Dynamics commences ultra low dose trials of radiopharmaceutical agents with D-SPECT technology

Cardiovascular imaging accounts for 30 percent of all the radiation patients receive in the U.S. and today, at the Society for Nuclear Medicine annual meeting, Spectrum Dynamics announced it has begun clinical studies to show that its D-SPECT™ technology can accommodate significantly lower doses of radiopharmaceutical agents so the total radiation exposure to patients and staff is much lower compared to conventional cardiac imaging.

10 Jun 2010

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.

10 Jun 2010

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.

10 Jun 2010

Study reveals insurance related differences in hospital mortality for AMI, stroke, pneumonia

An analysis of over 150,000 hospital discharges has revealed that there are significant insurance related differences in hospital mortality, length of stay, and costs among working-age Americans (age 18-64 years) hospitalized for acute myocardial infarction (AMI), stroke, or pneumonia. These three conditions are among the leading causes of non-cancer in-patient deaths in patients under 65 years old. The analysis is published today in the Journal of Hospital Medicine.

10 Jun 2010

Voices Against Brain Cancer's fifth annual gala to fight brain cancer

Voices Against Brain Cancer's fifth annual gala, Sounding Off For A Cure, to fight brain cancer. Proceeds from the event will benefit innovative brain cancer research programs at, Columbia, Cornell, Duke, Harvard, Memorial Sloan-Kettering, University of Michigan, University of Pittsburg and Brookhaven National Laboratory.

10 Jun 2010

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Genzyme Corporation and Carl C. Icahn and certain of his affiliated private investment funds announced today an agreement to settle their proxy contest.

10 Jun 2010

Cancer News and Research

Latest Cancer News and Research

NanoString Technologies launches new solution to detect CNVs in human genomic samples

Nativis awarded patents in Japan, China, India for drug signal technology

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

Goodmans Interior Structures and Shore Memorial Hospital receives CEO Cancer Gold Standard accreditation

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Clarient becomes preferred genetic testing lab for Generation Health

Human Genome Sciences submits BLA for BENLYSTA to FDA

PCI Biotech rights issue oversubscribed

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

Caregiver's guide on avoiding life-threatening swallowing problems

Study to understand process of telomere shortening

Investigative Workshop aims to discuss current achievements, challenges in modeling solid tumors

Spectrum Dynamics commences ultra low dose trials of radiopharmaceutical agents with D-SPECT technology

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Study reveals insurance related differences in hospital mortality for AMI, stroke, pneumonia

Voices Against Brain Cancer's fifth annual gala to fight brain cancer

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in